

## RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

### A New Method for Determining Concentrations of Direct Oral Anticoagulants

Bloemen, Saartje; Zwaveling, Suzanne; Douxfils, Jonathan; Peters, T.; Wagenvoord, Rob; Hemker, Hendrick Coenraad; Mullier, François; de Laat, Bas; Roest, Mark; Kremers, Romy

*Published in:*

Research and practice in thrombosis and haemostasis

*Publication date:*  
2017

*Document Version*  
Publisher's PDF, also known as Version of record

#### [Link to publication](#)

*Citation for pulished version (HARVARD):*

Bloemen, S, Zwaveling, S, Douxfils, J, Peters, T, Wagenvoord, R, Hemker, HC, Mullier, F, de Laat, B, Roest, M & Kremers, R 2017, A New Method for Determining Concentrations of Direct Oral Anticoagulants. in *Research and practice in thrombosis and haemostasis: Abstracts of the XXVI Congress of the International Society on Thrombosis and Haemostasis, July 8–13, 2017*. vol. 1, pp. 968, XXVI Congress of the International Society on Thrombosis and Haemostasis, Berlin, Germany, 8/07/17.

#### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

#### **Take down policy**


If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## PB 1199 | A New Method for Determining Concentrations of Direct Oral Anticoagulants

S. Bloemen<sup>1,2</sup>, S. Zwaveling<sup>1,2</sup>, J. Douxfils<sup>3</sup>, T. Peters<sup>1,2</sup>, R. Wagenvoort<sup>1,2</sup>, H.C. Hemker<sup>1,2</sup>, F. Mullier<sup>3,4</sup>, B. de Laat<sup>1,2</sup>, M. Roest<sup>1,2</sup>, R. Kremers<sup>1,2</sup>

<sup>1</sup>Synapse Research Institute, CARIM, Maastricht University, Maastricht, The Netherlands, <sup>2</sup>CARIM, Maastricht University, Department of Biochemistry, Maastricht, The Netherlands, <sup>3</sup>Namur Research Institute for Life Sciences, University of Namur, Department of Pharmacy, Namur, Belgium, <sup>4</sup>Université Catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center, Yvoir, Belgium

**Background:** Direct oral anticoagulants (DOACs) are commonly provided without monitoring. However, reliable assays to measure DOAC levels and activity in emergency situations are needed. We developed a test based on the inhibition of  $\alpha_2$ macroglobulin-thrombin ( $\alpha_2$ M-IIa)



**FIGURE 1** Dose-response of several DOAC concentrations at chosen  $\alpha_2$ M-Xa and  $\alpha_2$ M-IIa concentrations

**TABLE 1** Correlation (Spearman) of rivaroxaban or dabigatran concentration (as determined by the new assay) with TG and other calibrated assays

Assay	Correlation coefficient	p-value	Assay	Correlation coefficient	p-value
Rivaroxaban			Dabigatran		
Calibrated prothrombin time (ng/ml)	0.468	0.002	Activated partial thromboplastin time (s)	0.581	0.002
Dilute Russel viper venom time (s)	0.760	0.000	Dilute Russel viper venom time (s)	0.649	0.001
Biophen DiXal (ng/ml)	0.915	0.000	Hemoclot thrombin inhibitor (ng/ml)	0.391	0.097
TG endogenous thrombin potential(nM.min)	-0.525	0.000	Ecarin chromogenic assay (ng/ml)	0.591	0.001
TG Peak (nM)	-0.550	0.000	TG endogenous thrombin potential(nM.min)	-0.323	0.100
TG lag time (min)	0.671	0.000	TG Peak (nM)	-0.354	0.201
TG time-to-peak (min)	0.702	0.000	TG lag time (min)	0.423	0.028
			TG time-to-peak (min)	0.339	0.084

by dabigatran (DAB) and of  $\alpha_2$ M-factor Xa ( $\alpha_2$ M-Xa) by rivaroxaban (RIV), making it possible to evaluate both DOAC classes in combination with thrombin generation (TG).

**Aims:** To quantify DOAC levels and activity in plasma.

**Methods:** Consenting patients using RIV (n=50) and DAB (n=28) were included. TG was performed in platelet poor plasma (5 pM tissue factor), with idarucizumab in calibrator wells for DAB samples. The new DOAC assays measured the effect of diluted plasma samples on Z-Gly-Gly-Arg-AMC conversion by  $\alpha_2$ M-Xa or  $\alpha_2$ M-IIa. The slopes of these curves were compared to a reference curve with known DOAC concentrations. DOAC levels were also estimated by 'classical' assays. Spearman correlation coefficients were determined.

**Results:** A concentration of 30 nM  $\alpha_2$ M-Xa or  $\alpha_2$ M-IIa was optimal to measure 50-500 nM RIV/DAB and 90 nM  $\alpha_2$ M-Xa or 70 nM  $\alpha_2$ M-IIa, respectively were optimal for 500-1000 nM RIV/DAB (Fig.1).

The intra- and inter-assay CV were below 2.5 % and 5% (n=2). Both the RIV and DAB assay correlated with TG parameters. The RIV assay correlated with 'classical' assays and had a very good correlation with Biophen DiXal. The DAB assay did not correlate with hemoclot thrombin inhibitor (probably since DAB concentrations were too low), but showed variable correlation with the other assays (Table1).

**Conclusions:** The new DOAC assays show good correlations with other assays that were confirmed to accurately assess DOAC levels (particularly the RIV assay with the Biophen DiXal, which had the best correlation with mass spectrometry). Our assay can simultaneously evaluate DOAC concentrations as well as the DOACs effect on thrombin generation, providing an overview of the anticoagulation status of a patient in relation to circulating DOAC levels.